the aid library

LIST OPTIONS

Filter

3646

Download (198)

View PDF (362)

WHO Good Governance for Medicines programme. an innovative approach to prevent corruption in the pharmaceutical sector

Baghdadi-Sabeti , G.; and F. Serhan World Health Organization WHO (2010) C_WHO

Compilation of country case studies and best practices. World Health Report (2010) Background Paper, 25

Download (158)

View PDF (102)

Comprehensive Overview of Malaria: Epidemiology, Impact, and Prevention Strategies - last update 2022-06-14

International Federation of Red Cross and Red Crescent Societies (IFRC) (2022) C2

The document provides a comprehensive overview of malaria, covering its global impact, transmission, symptoms, diagnosis, treatment, prevention strategies, and the role of public health interventions—especially in high-risk regions like sub-Saharan Africa—to reduce its incidence and mortality.

Download (200)

View PDF (360)

Tracking 100 Core Indicators for Cameroon in 2017

Ministry of Public Health, Cameroon; World Health Organization WHO (2017) C1

Download (627)

View PDF (889)

The National Strategic Plan for comprehensive and multi-sectoral response to HIV/AIDS III (2011-2015) in Cambodia

National AIDS Authority (2010) CC

External Link

Shifting official development assistance during COVID-19: earmarking, donor concentration and loans

Woskie L., Wenham C. BMJ Global Health (2024) CC

In contrast to bilateral aid, aid disbursed from multilateral institutions increased significantly at the onset of the COVID-19 pandemic. Yet, at a time when a coherent and effective multilateral response is needed most, the COVID-19 pandemic revealed a shifting landscape of donor agencies that... more

Download (17)

View PDF (12)

Community deployment of intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine: a field guide

World Health Organization WHO (2024) C_WHO

The document outlines essential steps and provides guidance to countries on the adoption and deployment of c-IPTp so that it is integrated into the existing health system. It draws upon best practices and lessons learned from pilot implementation experiences in eight African countries and targets st... more

Download (436)

View PDF (536)

Diagnostic test for surveillance of lymphatic filariasis: target product profile

World Health Organization WHO (2021) C_WHO

The purpose of this TPP is to communicate the minimum and ideal characteristics desired to meet the need for discriminating low levels of risk for transmission, i.e. targeted prevalence thresholds in the surveyed areas. An in vitro diagnostic test is needed for the detection of analyte(s) specific t... more

Download (261)

View PDF (224)

AZD1222 vaccine against COVID-19 developed by Oxford University and Astra Zeneca: Background paper

World Health Organization WHO, SAGE (2021) C_WHO

10 February 2021. Draft

Download (554)

View PDF (746)

ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic

European Society of Cardiology (2020) C1

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV‑2) causing coronavirus disease 2019 (COVID-19) has reached pandemic levels; Patients with cardiovascular (CV) risk factors and established cardiovascular disease (CVD) represent a vulnerable population when suffering from COVID-19; Patien... more

External Link

Taenia solium taeniosis/cysticercosis and the co-distribution with schistosomiasis in Africa

Braae, U.; Saarnak, C.; Mukaratirwa, S. et al. Parasites and Vectors (2015) CC

The major neglected tropical diseases, Taenia solium taeniosis/cysticercosis and schistosomiasis caused by Schistosoma mansoni or S. haematobium are presumed to be widely distributed in Africa. Taenia solium taeniosis/ cysticercosis has been reported as an emerging disease in different regions of Af... more

Download (209)

View PDF (243)

Worldwide rates of diagnosis and effective treatment for cystic fibrosis

Guo, J.; Garratt, A.; Hill, A. Journal of Cystic Fibrosis (2022) CC

Time has seen management for Cystic Fibrosis (CF) advance drastically, most recently in the development of the disease-modifying triple combination therapy ivacaftor/tezacaftor/elexacaftor. There is currently limited evidence regarding both the global epidemiology of CF and access to this transforma... more

Download (360)

View PDF (460)

Budgeting application tool

UNITAID, WHO, Global Laboratory Initiative, et. al (2015) C_WHO

User manual.

Download (417)

View PDF (634)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (441)

View PDF (1168)

Kenya National Clinical Nutrition and Detection Reference Manual

Kenya Ministry of Health (2010) CC

Download (221)

View PDF (421)

‘Virus Carriers’ and HIV testing: navigating Ukraine’s HIV policies and programming for female sex workers

A. Tokar; J. Osborne; K. Slobodianiuk; et al. BMC Public Health (BioMed Central); Health Research Policy and Systems (2019) CC

Tokar et al. Health Research Policy and Systems (2019) 17:23 https://doi.org/10.1186/s12961-019-0415-4

Download (249)

View PDF (345)

Lessons Learned in Scaling Up TB/HIV Collaborative Activities

M. Dallao; R. L’Herminez; B. Weil; et al. USAID From the American People; The Tuberculosis Coalition for Technical Assistance (TBCTA); Family Health International (FHI) (2020) C2

Accessed: 10.03.2020